Warner Chilcott PLC (WCRX): Today's Featured Drugs Laggard

Warner Chilcott ( WCRX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1%. By the end of trading, Warner Chilcott fell 12 cents (-0.7%) to $17.06 on average volume. Throughout the day, three million shares of Warner Chilcott exchanged hands as compared to its average daily volume of 3.4 million shares. The stock ranged in price between $16.95-$17.85 after having opened the day at $17.39 as compared to the previous trading day's close of $17.18. Other company's within the Drugs industry that declined today were: Aoxing Pharmaceutical Company ( AXN), down 21.2%, StemCells ( STEM), down 13.2%, China Pharma ( CPHI), down 11.8%, and Meridian Bioscience ( VIVO), down 9.2%.

Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. Warner Chilcott has a market cap of $4.26 billion and is part of the health care sector. The company has a P/E ratio of 13.3, below the average drugs industry P/E ratio of 14.1 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.1% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Warner Chilcott as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins, compelling growth in net income and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated.

On the positive front, XenoPort ( XNPT), up 23.7%, iBio ( IBIO), up 13.2%, Synta Pharmaceuticals ( SNTA), up 12.2%, and Sangamo BioSciences ( SGMO), up 9.1%, were all gainers within the drugs industry with Abbott Laboratories ( ABT) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

U.S. Crude Oil Hits Fresh 3-Year Highs as Gas Prices March to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gas Prices March to $3 a Gallon

J.C. Penney Shares Sink 10% as Marvin Ellison Resigns to Join Lowe's

J.C. Penney Shares Sink 10% as Marvin Ellison Resigns to Join Lowe's

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday